TrialSignal transduction and targeted therapy2025

Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis.

Xiaoxiao Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.